Contineum CFO granted 192,000 stock options

Contineum Therapeutics reported a new equity award for its Chief Financial Officer, Peter Slover.

Accepted by SEC EDGAR 01/30/2026 - 04:57 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Contineum Therapeutics reported a new equity award for its Chief Financial Officer, Peter Slover. On 01/30/2026, he received a grant of stock options to buy 192,000 shares of Class A common stock at an exercise price of $14.26 per share under the company’s 2024 Equity Incentive Plan. These options vest in equal monthly installments over 48 months, conditioned on his continuous service, and he beneficially owns 192,000 derivative securities directly after the grant.

Insider Trade Summary

Grant/Award: 192,000 shares

Grant/Award 1 txn

Insider Slover Peter T

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	192,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 192,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 192,000 contracts (Direct)

Footnotes (1)

1. F1. Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CTNM disclose for its CFO Peter Slover?

Contineum Therapeutics disclosed a grant of stock options to CFO Peter Slover. On 01/30/2026, he received 192,000 stock options under the 2024 Equity Incentive Plan, exercisable for Class A common stock at $14.26 per share, vesting over 48 months of continuous service.

How many Contineum Therapeutics (CTNM) options were granted to the CFO?

The CFO received 192,000 stock options. These options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan and give a right to buy Class A common stock, vesting in equal monthly installments over 48 months, subject to his continuous service with the company.

What is the exercise price of the CTNM stock options granted to the CFO?

The stock options granted to the CFO have an exercise price of $14.26 per share. They are options to purchase Class A common stock, issued under the 2024 Equity Incentive Plan, and they vest monthly over 48 months as long as his service with the company continues.

Over what period do the CTNM CFO’s stock options vest?

The CFO’s stock options vest over 48 months. The options vest in equal monthly installments, meaning a portion becomes exercisable each month, and vesting is conditioned on the reporting person’s continuous service with Contineum Therapeutics throughout that period.

Under which plan were the Contineum Therapeutics (CTNM) options granted?

The options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan. This plan governs the stock option award of 192,000 options to the CFO, which vest in equal monthly installments over 48 months, subject to his continuous service with the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Slover Peter T

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.26	01/30/2026		A		192,000		(1)	01/29/2036	Class A Common Stock	192,000	$0	192,000	D

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.

	/s/ Peter Slover	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.